An in vitro model that can distinguish between effects on angiogenesis and on established vasculature: actions of TNP-470, marimastat and the tubulin-binding agent Ang-510.

@article{vanWijngaarden2010AnIV,
  title={An in vitro model that can distinguish between effects on angiogenesis and on established vasculature: actions of TNP-470, marimastat and the tubulin-binding agent Ang-510.},
  author={Jens van Wijngaarden and Thomas J. A. Snoeks and Ermond R. van Beek and Henny Bloys and Eric L. Kaijzel and Victor W. M. van Hinsbergh and Clemens W. G. M. L{\"o}wik},
  journal={Biochemical and biophysical research communications},
  year={2010},
  volume={391 2},
  pages={
          1161-5
        }
}
View on PubMed
doi.org
10 Citations
Background Citations
5
Methods Citations
2

Figures from this paper

10 Citations

Citation Type

Citation Type

Inhibitory effects of Yangzheng Xiaoji on angiogenesis and the role of the focal adhesion kinase pathway.
TLDR
It was demonstrated that the focal adhesion kinase (FAK) inhibitor PF557328 had a significant synergistic effect on DME25-induced inhibition of cell adhesion, migration and tube formation, and that Yangzhen Xiaoji has a marked effect on angiogenesis, in vitro.
Preclinical Development 2-Methoxyestradiol Analogue ENMD-1198 Reduces Breast Cancer-Induced Osteolysis and Tumor Burden Both In Vitro and In Vivo
TLDR
ENMD-1198 showed both antiangiogenic and vascular disruptive properties and was capable of protecting the bone against tumor-induced osteolysis, and was combined with low-dose metronomic cyclophosphamide and the bisphosphonate risedronic acid, leading to a mild increase in treatment efficacy.
2-Methoxyestradiol Analogue ENMD-1198 Reduces Breast Cancer-Induced Osteolysis and Tumor Burden Both In Vitro and In Vivo
TLDR
ENMD-1198 showed both antiangiogenic and vascular disruptive properties and was capable of protecting the bone against tumor-induced osteolysis, and was combined with low-dose metronomic cyclophosphamide and the bisphosphonate risedronic acid for a mild increase in treatment efficacy.
The Research Progress of Matrix Metalloproteinases in Invasion and Metastasis of Gastric Cancer
TLDR
The role of M MPs in the invasion and metastasis of gastric cancer is introduced and the drugs affected on MMPs had reached the stage of clinical trials.
Role of the Cytoskeleton in Formation and Maintenance of Angiogenic Sprouts
TLDR
Evidence for regulatory molecules and pharmacological compounds that affect actin, microtubule and intermediate filament dynamics to alter various steps of angiogenesis, including endothelial sprout formation and maintenance are discussed.
A C-terminal fragment BIGH3 protein with an RGDRGD motif inhibits corneal neovascularization in vitro and in vivo.
The fetal mouse metatarsal bone explant as a model of angiogenesis
TLDR
The mouse fetal metatarsal provides a unique tool for studying angiogenesis and allows the analysis of blood vessel growth, and the mechanisms underpinning this process, in a multicellular microenvironment that drives the formation of a robust and complex vascular network in the absence of exogenous growth factors.
ROL DE LAS METALOPROTEINASAS Y SUS INHIBIDORES EN PATOLOGÍA TUMORAL
TLDR
Due to their role in cancer biology, MMPs are potential targets for future therapeutic strategies of this malignant disease.
Human Adipose Stromal Cell Angiogenesis Assay: Development of Stimulation Medium and Set-up of Cell Characterization
TLDR
The next generation of scientists and decision-makers will have to consider whether or not to use nanofiltration membranes for the recovery of phosphorous with a second type of technology called a “silicon-like substance”.
The Research Progress of Matrix Metalloproteinases in Invasion and Metastasis of Gastric Cancer
TLDR
The most important thing for treating gastric cancer is to prevent its invasion and metastasis, which are the most common causes of treatment failure and mortality.

References

SHOWING 1-10 OF 41 REFERENCES
Current development status of small-molecule vascular disrupting agents.
TLDR
The VDA compounds combretastatin A4 phosphate and 5,6-dimethylxantlenone-4-acetic acid are being evaluated in phase II clinical trials in combination with conventional cytotoxic therapies for the potential treatment of cancer.
Cytostatic inhibition of endothelial cell growth by the angiogenesis inhibitor TNP-470 (AGM-1470).
TLDR
The results suggest that TNP-470 exerts its specific anti-angiogenic action by inhibiting cytostatically growth of endothelial cells in a relatively specific manner.
Angiogenesis, neovascular proliferation and vascular pathophysiology as targets for cancer therapy
TLDR
A body of evidence that vascular-mediated damage occurs in murine tumours after many existing forms of anti-tumour therapy is rapidly accumulating means that a change in the approach to experimental cancer therapy is needed to ensure that this important new avenue is fully investigated.
Cell cycle inhibition by the anti-angiogenic agent TNP-470 is mediated by p53 and p21WAF1/CIP1.
TLDR
It is reported that treatment of endothelial and other drug-sensitive cell types leads to the activation of the p53 pathway, causing an accumulation of the G(1) cyclin-dependent kinase inhibitor p21(WAF1/CIP1).
Review article: angiogenesis, neovascular proliferation and vascular pathophysiology as targets for cancer therapy.
  • J. Denekamp
  • Medicine, Biology
    The British journal of radiology
  • 1993
TLDR
A change in the approach to experimental cancer therapy is needed to ensure that this important new avenue is fully investigated and the "hallmarks" of vascular mediated injury and the means by which this can be distinguished from direct cell kill are identified.
Vascular disrupting agents: a new class of drug in cancer therapy.
  • A. Gaya, G. Rustin
  • Medicine, Biology
    Clinical oncology (Royal College of Radiologists (Great Britain))
  • 2005
Small molecule vascular disrupting agents: potential new drugs for cancer treatment.
  • S. Cai
  • Biology, Chemistry
    Recent patents on anti-cancer drug discovery
  • 2007
TLDR
This review will focus on recent progress in the discovery and development of small molecule VDAs, including recently published patent applications and issued patents related with small moleculeVDAs.
Vascular Targeting Agents as Cancer Therapeutics
  • P. Thorpe
  • Biology
    Clinical Cancer Research
  • 2004
TLDR
VTAs can kill indirectly the tumor cells that are resistant to conventional antiproliferative cancer therapies, i.e., cells in areas distant from blood vessels where drug penetration is poor, and hypoxia can lead to radiation and drug resistance.
Dual targeting of tumor vasculature: combining Avastin and vascular disrupting agents (CA4P or OXi4503).
TLDR
Vascular-directed therapies that include both antiangiogenic and vascular disrupting therapeutics can result in significantly enhanced antitumor effects.
Vascular damaging agents.
  • D. Patterson, G. Rustin
  • Biology, Medicine
    Clinical oncology (Royal College of Radiologists (Great Britain))
  • 2007
...
1
2
3
4
5
...